Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Keros Therapeutics, Inc. - common stock (NQ:KROS)

16.57 -0.01 (-0.06%)
Streaming Delayed Price Updated: 10:50 AM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Keros Therapeutics, Inc. - common stock

< Previous 1 2 3 Next >
News headline image
Keros Therapeutics Inc (NASDAQ:KROS) Emerges as a High-Growth Momentum Breakout Candidate ↗
Keros Therapeutics exemplifies a high-growth momentum strategy, combining explosive revenue growth, perfect technical ratings, and a defined breakout setup for potential entry. 
Via Chartmill
News headline image
Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst ↗
BofA's Zemansky downgraded Keros to Neutral, citing limited near-term upside, cautious sentiment, and unresolved investor concerns. 
Via Benzinga
News headline image
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45% ↗
Keros ends PAH development of cibotercept after Phase 2 safety issues, including pericardial effusions, and plans to cut 45% of workforce amid review. 
Via Benzinga
News headline image
Deal Dispatch: Harley-Davidson To Wipe Out? Plus, Prada's Versace Purchase Garners A Fashionable Price ↗
Things are hog wild at Harley-Davidson; Plus, Impresoft, Keros Therapeutics and Rivalry Corp. are all itching for a deal. 
Via Benzinga
News headline image
Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan ↗
Keros Therapeutics launches strategic review and adopts rights plan after investor activity signals potential changes in company control. 
Via Benzinga
News headline image
Analyst Expectations For Keros Therapeutics's Future ↗
 
Via Benzinga
News headline image
Deep Dive Into Keros Therapeutics Stock: Analyst Perspectives (11 Ratings) ↗
 
Via Benzinga
News headline image
These stocks are gapping in today's session ↗
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
News headline image
Keros Therapeutics Adopts Defense Strategy Against Potential Hostile Takeover, Explores Sale: Retail’s Overjoyed ↗
The company said the plan aims to reduce the likelihood of any entity or person gaining control of Keros through open-market accumulation without paying all stockholders an appropriate control... 
Via Stocktwits
News headline image
Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump ↗
 
Via Benzinga
News headline image
PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Where Keros Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Keros Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Forecasting The Future: 7 Analyst Projections For Keros Therapeutics ↗
 
Via Benzinga
News headline image
Crude Oil Rises Sharply; JPMorgan Chase Earnings Top Views ↗
 
Via Benzinga
News headline image
Nasdaq Surges Over 2%; Goldman Sachs Posts Upbeat Q4 Results ↗
 
Via Benzinga
News headline image
Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes ↗
The company’s stock declined nearly 60% in 2024 and has lost an additional 21% in 2025, with this latest setback further dampening investor confidence. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Dow Tumbles 200 Points; Liquidity Services Shares Spike Higher ↗
 
Via Benzinga
Topics Stocks
News headline image
Gold Falls Sharply; Adobe Shares Dip After Weak Revenue Outlook ↗
 
Via Benzinga
News headline image
Nasdaq Down 50 Points; US Initial Jobless Claims Rise ↗
 
Via Benzinga
News headline image
Keros Therapeutics Loses 75% Value In A Single Session - Here's Why ↗
Keros Therapeutics halts high-dose cibotercept treatment in the TROPOS trial after safety concerns, with topline results anticipated in Q2 2025. 
Via Benzinga
News headline image
Keros Therapeutics Plummets 73% On Unexpected Side Effects In Hypertension Study ↗
The company is continuing to test the lowest dose of its pulmonary arterial hypertension drug. 
Via Investor's Business Daily
News headline image
Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst ↗
Takeda inks a licensing deal with Keros for elritercept, a late-stage anemia drug, and plans a Phase 3 trial in myelodysplastic syndromes. 
Via Benzinga
News headline image
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark ↗
Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86. 
Via Investor's Business Daily
News headline image
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
KROS Stock Earnings: Keros Therapeutics Misses EPS for Q2 2024 ↗
KROS stock results show that Keros Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.